Reversible Covalent Nitrile Warheads in Drug Discovery
The nitrile group has become one of the most extensively studied electrophilic warheads in reversible covalent inhibitor design. Unlike more reactive warheads such as acrylamides, nitriles react with an active-site serine or cysteine nucleophile to form a reversible imidate or thioimidate adduct. Because these covalent bonds exist in equilibrium with the free enzyme and inhibitor, they combine the affinity benefits of covalent engagement with the reversibility typically associated with non-covalent drugs. This comparatively mild intrinsic reactivity is often viewed as an advantage. Nitriles generally require precise positioning within the enzyme active site before reacting, reducing the likelihood of indiscriminate modification of off-target nucleophiles while still allowing the covalent interaction to contribute meaningfully to potency and target residence time. Multiple approved medicines now demonstrate the versatility of this chemistry across different target classes. Saxagliptin, approved in 2009 for type 2 diabetes, uses a nitrile warhead to form a reversible covalent adduct with the catalytic serine of dipeptidyl peptidase-4 \(DPP-4\). Nirmatrelvir, approved in 2022, the antiviral component of Paxlovid, employs the same warhead to reversibly engage the catalytic cysteine of the SARS-CoV-2 main protease \(Mpro\). The ability of nitriles to target both serine and cysteine nucleophiles across such diverse therapeutic areas illustrates how adaptable this warhead can be when supported by appropriate molecular recognition. A 2025 structure-activity study of SARS-CoV-2 Mpro inhibitors provides an interesting illustration of the trade-offs involved in warhead selection. The work highlights that selecting a covalent warhead is rarely a question of maximising intrinsic reactivity alone. Potency, selectivity, pharmacokinetics, safety, and the overall binding mechanism must all be balanced, with the optimal choice depending on the biological target. Explore our range of building blocks using the advanced search tools at https://lnkd.in/eVbfw6Ua. Further reading: 1\)Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases https://lnkd.in/e7cu5tXh 2\) Key advances in the development of reversible covalent inhibitors https://lnkd.in/efpQUSPk 3\) Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding https://lnkd.in/e5H-Ch\_D